Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus | Zendy

Ti Yin | Zendy; ShuChen Kuo | Zendy; Yea-Yuan Chang | Zendy; YungTai Chen | Zendy; Kai-Wei Katherine Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus

Author(s) -

Ti Yin,

ShuChen Kuo,

Yea-Yuan Chang,

YungTai Chen,

Kai-Wei Katherine Wang

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-3778

Subject(s) - medicine , hazard ratio , verapamil , type 2 diabetes mellitus , cohort , confidence interval , incidence (geometry) , diabetes mellitus , population , cohort study , endocrinology , calcium , optics , physics , environmental health

The mechanism of the beneficial effect of calcium-channel blockers (CCBs), especially verapamil, on the development of type 2 diabetes mellitus (T2DM) has been described. This study compared the incidence of T2DM in adults prescribed oral verapamil and propensity score-matched adults prescribed other oral CCBs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research